{"id":"ibi308","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Decreased appetite"},{"rate":null,"effect":"Immune-related adverse events (pneumonitis, hepatitis, colitis)"},{"rate":null,"effect":"Infusion-related reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IBI308 is a humanized monoclonal antibody targeting programmed death receptor 1 (PD-1). By blocking PD-1, the drug prevents tumor cells from suppressing T cell-mediated immunity, allowing the immune system to recognize and attack cancer cells more effectively. This mechanism is similar to other checkpoint inhibitors and is designed to enhance endogenous anti-tumor immunity across multiple cancer types.","oneSentence":"IBI308 is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby restoring anti-tumor immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:48:11.011Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Gastric cancer"},{"name":"Esophageal cancer"}]},"trialDetails":[{"nctId":"NCT07474103","phase":"NA","title":"SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-11-30","conditions":"Rectal Cancer, Adenocarcinoma","enrollment":49},{"nctId":"NCT05171660","phase":"PHASE3","title":"Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-02-08","conditions":"Colorectal Cancer Stage IV","enrollment":446},{"nctId":"NCT05472948","phase":"PHASE2","title":"Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-02-01","conditions":"Adenocarcinoma of Small Intestine, Appendix Carcinoma, Metastatic","enrollment":36},{"nctId":"NCT06220318","phase":"PHASE1, PHASE2","title":"Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fujian Haixi Pharmaceuticals Co., Ltd.","startDate":"2023-07-19","conditions":"Solid Tumor","enrollment":155},{"nctId":"NCT05026736","phase":"PHASE2","title":"Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma, the SiARa Cancer Study","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-08-23","conditions":"Locally Advanced Angiosarcoma, Metastatic Angiosarcoma, Recurrent Angiosarcoma","enrollment":6},{"nctId":"NCT04548440","phase":"PHASE2","title":"Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients","status":"COMPLETED","sponsor":"Sun Yat-Sen University Cancer Center","startDate":"2020-08-31","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":50},{"nctId":"NCT07007767","phase":"PHASE2","title":"Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies）","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-06-15","conditions":"Colorectal Cancer Metastatic","enrollment":32},{"nctId":"NCT06900218","phase":"PHASE3","title":"PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-05-01","conditions":"Nasopharyngeal Carcinoma (NPC)","enrollment":664},{"nctId":"NCT03812549","phase":"PHASE1","title":"Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC Patients","status":"COMPLETED","sponsor":"Sichuan University","startDate":"2019-01-18","conditions":"Stage IV NSCLC","enrollment":29},{"nctId":"NCT04297280","phase":"PHASE2","title":"TACE Combined with Anti-PD-1 Antibody in Patients with Advanced Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Fudan University","startDate":"2020-04-29","conditions":"Hepatocellular Carcinoma","enrollment":25},{"nctId":"NCT05504278","phase":"PHASE1","title":"Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation","status":"RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2022-09-20","conditions":"Advanced Non-Small Cell Lung Cancer","enrollment":144},{"nctId":"NCT06204094","phase":"PHASE2","title":"Node-sparing Radiotherapy Combined with Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer","status":"RECRUITING","sponsor":"Jinhua Central Hospital","startDate":"2024-02-05","conditions":"Locally Advanced Rectal Cancer","enrollment":37},{"nctId":"NCT06584032","phase":"PHASE3","title":"Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer","status":"RECRUITING","sponsor":"Hutchmed","startDate":"2024-12-12","conditions":"Advanced Endometrial Cancer","enrollment":412},{"nctId":"NCT05522231","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hutchmed","startDate":"2022-10-27","conditions":"Advanced Renal Cell Carcinoma","enrollment":265},{"nctId":"NCT05017103","phase":"PHASE2","title":"Sintilimab for the Treatment of Locally Advanced, Metastatic, Recurrent, or Unresectable Undifferentiated Pleomorphic Sarcoma, SiARa Cancer Study","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-07-13","conditions":"Locally Advanced Undifferentiated Pleomorphic Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Recurrent Undifferentiated Pleomorphic Sarcoma","enrollment":6},{"nctId":"NCT03872661","phase":"PHASE2","title":"Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2019-03-01","conditions":"Lung Cancer Stage III","enrollment":36},{"nctId":"NCT04940546","phase":"PHASE1, PHASE2","title":"Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in PMMR/MSS CRLM Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2021-06-16","conditions":"Colorectal Cancer Metastatic","enrollment":36},{"nctId":"NCT03869034","phase":"PHASE2","title":"HAIC Combined with PD-1 Inhibitor in Potentially Resectable Locally Advanced HCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2019-03-25","conditions":"Hepatocellular Carcinoma","enrollment":40},{"nctId":"NCT04973293","phase":"NA","title":"Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2022-10-01","conditions":"Lung Neoplasm Malignant","enrollment":20},{"nctId":"NCT06313190","phase":"PHASE2","title":"Combination of SBRT and Immunotherapy in Small Hepatocellular Carcinoma (HSBRT2402)","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-04-05","conditions":"Hepatocellular Carcinoma","enrollment":140},{"nctId":"NCT04401813","phase":"PHASE1","title":"Efficacy and Safety of IBI310 Combined with Sintilimab in Patients with Advanced Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2020-06-16","conditions":"Advanced Hepatocellular Carcinoma","enrollment":97},{"nctId":"NCT04735861","phase":"PHASE2","title":"Sintilimab Plus Bevacizumab in Recurrent/Persistent Ovarian Clear Cell Carcinoma","status":"COMPLETED","sponsor":"Tongji Hospital","startDate":"2021-04-07","conditions":"Ovarian Clear Cell Carcinoma","enrollment":38},{"nctId":"NCT06089369","phase":"PHASE3","title":"Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2024-06-01","conditions":"Hepatocellular Carcinoma","enrollment":360},{"nctId":"NCT06321913","phase":"PHASE2","title":"Study of IBI343 in Subjects With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Harbin Medical University","startDate":"2024-03-15","conditions":"Advanced Gastric/Gastroesophageal Junction Adenocarcinoma","enrollment":25},{"nctId":"NCT06240689","phase":"PHASE2","title":"A Prospective Randomized Controlled Study of Immune Checkpoint Maintenance Therapy After Radiotherapy and Chemotherapy for Locally Advanced Head and Neck Tumors Based on Peripheral Blood CD8Tex Detection in Peripheral Blood","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-01-25","conditions":"Locally Advanced Head and Neck Squamous Cell Carcinoma","enrollment":104},{"nctId":"NCT05164458","phase":"PHASE1","title":"Safety and Efficacy of IBI389 Single Agent, and in Combination With Sintilimab, in Patients With Advanced Malignancies","status":"UNKNOWN","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2022-03-22","conditions":"Advanced Solid Tumors","enrollment":320},{"nctId":"NCT04590599","phase":"PHASE2","title":"A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2020-12-08","conditions":"Advanced Cervical Cancer","enrollment":205},{"nctId":"NCT03802240","phase":"PHASE3","title":"Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2019-07-11","conditions":"Non-Squamous Non-Small Cell Lung Cancer","enrollment":492},{"nctId":"NCT06089382","phase":"PHASE3","title":"A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2023-11-01","conditions":"Hepatocellular Carcinoma","enrollment":104},{"nctId":"NCT05337267","phase":"PHASE1","title":"Phase I Study of Sintilimab in Healthy Chinese Male Subjects","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2022-04-13","conditions":"Healthy Male Subjects","enrollment":117},{"nctId":"NCT05653180","phase":"PHASE1, PHASE2","title":"IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer","status":"UNKNOWN","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2023-03-10","conditions":"Advanced Biliary Tract Cancer","enrollment":20},{"nctId":"NCT03700476","phase":"PHASE3","title":"Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2018-12-21","conditions":"Nasopharyngeal Neoplasms","enrollment":425},{"nctId":"NCT05616390","phase":"PHASE2","title":"Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2022-11-09","conditions":"Hepatocellular Carcinoma","enrollment":30},{"nctId":"NCT04194359","phase":"PHASE2","title":"Sintilimab (IBI308) Combined With Bevacizumab + XELOX Regimen in Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2021-02-04","conditions":"Metastatic Colorectal Cancer, RAS Mutation, Microsatellite Stable","enrollment":25},{"nctId":"NCT04277663","phase":"PHASE3","title":"The Study of IBI310 in Combination With IBI308 Compared to High-Dose Interferon In Patients With Acral Melanoma That Has Been Removed by Surgery","status":"TERMINATED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2020-04-17","conditions":"Acral Melanoma That Has Been Removed by Surgery","enrollment":136},{"nctId":"NCT04675983","phase":"PHASE3","title":"A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106)","status":"TERMINATED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2021-03-10","conditions":"Gastric Adenocarcinoma","enrollment":36},{"nctId":"NCT03745170","phase":"PHASE3","title":"Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2018-12-19","conditions":"Gastric Cancer","enrollment":650},{"nctId":"NCT03629925","phase":"PHASE3","title":"Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2018-09-28","conditions":"Squamous NSCLC","enrollment":357},{"nctId":"NCT03150875","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2017-09-01","conditions":"Non-small Cell Lung Cancer","enrollment":290},{"nctId":"NCT03607539","phase":"PHASE3","title":"Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2018-08-23","conditions":"Lung Neoplasms","enrollment":397},{"nctId":"NCT03758001","phase":"PHASE1","title":"First in Human Study of IBI101 in Chinese Subjects With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2019-02-13","conditions":"Advanced Solid Tumor","enrollment":38},{"nctId":"NCT05029973","phase":"PHASE2","title":"HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2021-05-10","conditions":"Hepatocellular Carcinoma","enrollment":30},{"nctId":"NCT04833387","phase":"PHASE2","title":"PD-1 Antibody Following Preoperative Chemoradiotherapy for Locally Advanced pMMR/MSS Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2021-01-01","conditions":"Colorectal Carcinoma","enrollment":30},{"nctId":"NCT05429463","phase":"PHASE3","title":"Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE Ⅱ）","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-11-11","conditions":"Squamous Cell Non-small Cell Lung Cancer","enrollment":250},{"nctId":"NCT05621499","phase":"NA","title":"HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2022-11","conditions":"Hepatocellular Carcinoma","enrollment":60},{"nctId":"NCT05572463","phase":"PHASE1, PHASE2","title":"A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma","status":"WITHDRAWN","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2022-11-01","conditions":"Unresectable Cutaneous Melanoma, Metastatic Cutaneous Melanoma","enrollment":""},{"nctId":"NCT05617430","phase":"PHASE2","title":"Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2022-11-02","conditions":"Hepatocellular Carcinoma","enrollment":43},{"nctId":"NCT02937116","phase":"PHASE1","title":"First in Human Study of IBI308 in Chinese Subjects With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2016-10-19","conditions":"Cancer, Solid Tumor","enrollment":233},{"nctId":"NCT05524155","phase":"PHASE2","title":"Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver Metastasis","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2022-09","conditions":"Colorectal Cancer, Liver Metastasis","enrollment":30},{"nctId":"NCT03946969","phase":"PHASE2","title":"Sintilimab in Combination With Chemotherapy in Neoadjuvant Treatment of Potentially Resectable Esophageal Cancer","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2019-05-09","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":30},{"nctId":"NCT04459611","phase":"PHASE2","title":"Neoadjuvant of Sintilimab Combined With Chemotherapy for Resectable NSCLC（neoSCORE）","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-07-01","conditions":"Non-small Cell Lung Cancer","enrollment":60},{"nctId":"NCT05201859","phase":"PHASE2","title":"Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2022-03-29","conditions":"Nasopharyngeal Carcinoma","enrollment":150},{"nctId":"NCT05306847","phase":"PHASE2","title":"Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2022-04-01","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":93},{"nctId":"NCT05292417","phase":"PHASE2","title":"Radiotherapy in Combination With Sintilimab，GM-CSF and Fruquintinib in Patients With MSS mCRC","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2022-03-25","conditions":"Colorectal Neoplasms","enrollment":71},{"nctId":"NCT03830411","phase":"PHASE2","title":"A Study of Sintilimab Compared With Docetaxel or Pemetrexed as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer After Failure With Platinum-Containing Chemotherapy","status":"UNKNOWN","sponsor":"Xin-Hua Xu","startDate":"2019-03-13","conditions":"Nonsquamous Non-Small Cell Lung Cancer","enrollment":76},{"nctId":"NCT04982939","phase":"PHASE2","title":"Peri-operative Sintilimab in Combination With SOX in Locally Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2021-06-21","conditions":"Gastric Cancer, Perioperative, Sintilimab","enrollment":210},{"nctId":"NCT05002686","phase":"PHASE2, PHASE3","title":"Safety and Efficacy of Sintilimab in Combination With Chemoradiothrapy Followed by D2 Surgical Resection in Patients With Advanced Gastric Cancer With Retroperitoneal Lymph Node Metastasis","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2021-08-07","conditions":"Gastric Cancer","enrollment":60},{"nctId":"NCT04958473","phase":"PHASE2","title":"A Study of Sintilimab in Combination With Axitinib in Advanced Renal Cell Cancer","status":"UNKNOWN","sponsor":"Tianjin Medical University Second Hospital","startDate":"2021-08-01","conditions":"Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma","enrollment":40},{"nctId":"NCT03568539","phase":"PHASE1","title":"IBI308 in Subjects With Advanced/Metastatic Solid Malignancies","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2018-06-27","conditions":"Advanced/Metastatic Solid Malignancies","enrollment":39},{"nctId":"NCT04167293","phase":"PHASE2, PHASE3","title":"Combination of Sintilimab and Stereotactic Body Radiotherapy in Hepatocellular Carcinoma (ISBRT01)","status":"UNKNOWN","sponsor":"Mian XI","startDate":"2019-11-16","conditions":"Hepatocellular Carcinoma","enrollment":116},{"nctId":"NCT04052659","phase":"PHASE2","title":"Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCL","status":"UNKNOWN","sponsor":"Peking University","startDate":"2021-04-15","conditions":"Peripheral T-cell Lymphoma","enrollment":30},{"nctId":"NCT04042805","phase":"PHASE2","title":"Sintilimab Combined With Lenvatinib in Local Advanced Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Baocai Xing","startDate":"2019-08-01","conditions":"Hepatocellular Carcinoma","enrollment":36},{"nctId":"NCT03116152","phase":"PHASE2","title":"Study of IBI308 With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line Treatment","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2017-05-10","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":190},{"nctId":"NCT03794440","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.","status":"UNKNOWN","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2019-02-11","conditions":"Hepatocellular Carcinoma","enrollment":595},{"nctId":"NCT03228836","phase":"PHASE2","title":"Efficacy and Safety Evaluation of IBI308 in Patients With Extranodal NK/T Cell Lymphoma Patients","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2017-08-23","conditions":"Effect of Drugs","enrollment":28},{"nctId":"NCT04659434","phase":"PHASE2","title":"Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL","status":"UNKNOWN","sponsor":"Qian Wenbin","startDate":"2020-12-10","conditions":"Diffuse Large B Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma","enrollment":51},{"nctId":"NCT03114683","phase":"PHASE2","title":"Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2017-03-30","conditions":"Relapsed/Refractory Classical Hodgkin's Lymphoma","enrollment":96},{"nctId":"NCT04486287","phase":"PHASE2","title":"Sintilimab After Stereotactic Ablation Brachytherapy for Refractory Oligometastatic Non-Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Tianjin Medical University Second Hospital","startDate":"2020-09-01","conditions":"Oligometastasis, Lung Neoplasms","enrollment":44},{"nctId":"NCT04104074","phase":"PHASE1","title":"Safety and Efficacy of Radiotherapy Plus Sintilimab for HCC With Portal Vein Tumor Thrombosis","status":"UNKNOWN","sponsor":"Beijing Tsinghua Chang Gung Hospital","startDate":"2019-11-25","conditions":"Hepatocellular Carcinoma, Portal Vein Tumor Thrombosis","enrollment":20},{"nctId":"NCT03987867","phase":"PHASE1","title":"Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2019-06-01","conditions":"Non-small Cell Lung Cancer, First-line Treatment","enrollment":30},{"nctId":"NCT04371796","phase":"PHASE2","title":"Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC","status":"UNKNOWN","sponsor":"Sichuan Cancer Hospital and Research Institute","startDate":"2020-05-10","conditions":"Lung Diseases, Neoplasms, Respiratory Tract Diseases","enrollment":20},{"nctId":"NCT04300959","phase":"PHASE2","title":"Anlotinib in Combination With PD1 With Gemcitabine Plus(+)Cisplatin for Unresectable or Metastatic Biliary Tract Cancer","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2020-01-01","conditions":"Biliary Tract Cancer","enrollment":80},{"nctId":"NCT04065282","phase":"PHASE2","title":"The Purpose of This Study is to Evaluate the Efficacy and Safety of Sintilimab in Combination With Xelox as Neoadjuvant Therapy for Patients With Resectable Locally Advanced Gastric or Gastroesophageal Adenocarcinoma.","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2019-08-06","conditions":"Gastric Cancer","enrollment":36},{"nctId":"NCT04252365","phase":"PHASE2","title":"Sintilimab Versus Pembrolizumab for Advanced-stage Non-Small-Cell Lung Cancer","status":"UNKNOWN","sponsor":"Guangdong Association of Clinical Trials","startDate":"2020-03-01","conditions":"Nsclc","enrollment":20},{"nctId":"NCT04096911","phase":"PHASE2","title":"Combination of PD-1 Monoclonal Antibody and HPV Vaccine in Patients With Cervical Cancer","status":"UNKNOWN","sponsor":"Buhai Wang","startDate":"2019-07-31","conditions":"Uterine Cervical Neoplasms, Cervical Cancer, Cervical Neoplasms","enrollment":20},{"nctId":"NCT04089657","phase":"PHASE2","title":"Apatinib Plus Sintilimab in Advanced Gastric Cancer Refractory to at Least Two Previous Chemotherapy Regimens","status":"UNKNOWN","sponsor":"Fujian Cancer Hospital","startDate":"2019-12-01","conditions":"Advanced Metastatic Gastric Cancer","enrollment":40},{"nctId":"NCT03940001","phase":"EARLY_PHASE1","title":"A Study of Sintilimab Plus Chemoradiation Before Surgery for Esophageal Cancer","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2019-05-01","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":20},{"nctId":"NCT04065737","phase":"PHASE2","title":"Sintilimab to Prevent High-risk Oral Premalignant Lesions Cancerization","status":"UNKNOWN","sponsor":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","startDate":"2019-08-15","conditions":"Oral Cavity Cancer, Mouth Neoplasm, Precancerous Conditions","enrollment":29},{"nctId":"NCT04056949","phase":"PHASE2","title":"Efficacy and Safety of IBI308 and Paclitaxel/Albumin Paclitaxel for SCLC Patients Who Failed Etoposide Chemotherapy","status":"UNKNOWN","sponsor":"Junling Li","startDate":"2019-08-05","conditions":"Extensive-Stage Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT03975270","phase":"PHASE2","title":"Sintilimab in Combination With Nab-paclitaxel in Patients With HNSCC (Head and Neck Squamous Cell Carcinoma )","status":"UNKNOWN","sponsor":"Shengyu Zhou","startDate":"2019-07-20","conditions":"Head and Neck Squamous Cell Cancer","enrollment":41},{"nctId":"NCT03884192","phase":"PHASE3","title":"Consolidation Sintilimab After Concurrent Chemoradiation in Patients With Unresectable Stage III NSCLC","status":"UNKNOWN","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2018-12-12","conditions":"Carcinoma, Non-Small Cell Lung","enrollment":162},{"nctId":"NCT03874000","phase":"PHASE2","title":"Sintilimab Combined With Metformin in First-Line Chemotherapy Refractory Advanced NSCLC Patients","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2019-03-08","conditions":"Non Small Cell Lung Cancer","enrollment":43},{"nctId":"NCT03857815","phase":"PHASE2","title":"Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Patients With Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2019-03-25","conditions":"Hepatocellular Carcinoma","enrollment":30},{"nctId":"NCT03765775","phase":"PHASE2","title":"Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative","status":"UNKNOWN","sponsor":"First Hospital of Shijiazhuang City","startDate":"2018-11-20","conditions":"Carcinoma, Non-small Cell Lung Cancer, Lung Neoplasm","enrollment":20},{"nctId":"NCT03732430","phase":"PHASE2","title":"CT-Guided Adaptive Radiation Therapy Combine With Anti-PD-1 Antibody Adjuvant Immunotherapy for Thoracic Cancer Patients","status":"UNKNOWN","sponsor":"Taizhou Hospital","startDate":"2018-11-14","conditions":"Thoracic Malignancies","enrollment":45},{"nctId":"NCT03619824","phase":"PHASE2","title":"PD-1 Blockade Combined With Definitive Chemoradiation in Locoregionally-advanced Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2019-01","conditions":"Nasopharyngeal Neoplasms","enrollment":40},{"nctId":"NCT03628521","phase":"PHASE1","title":"First-line Combination Treatment Based on Anlotinib","status":"UNKNOWN","sponsor":"Shanghai Chest Hospital","startDate":"2018-07-20","conditions":"Lung Cancer, Advanced Stage","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Sintilimab"],"phase":"phase_3","status":"active","brandName":"IBI308","genericName":"IBI308","companyName":"Innovent Biologics (Suzhou) Co. Ltd.","companyId":"innovent-biologics-suzhou-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"IBI308 is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby restoring anti-tumor immune responses. Used for Non-small cell lung cancer, Gastric cancer, Esophageal cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":8,"withResults":4},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}